NICE final draft "no" for Sanofi's Jevtana
Pharma Times
In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) says it does not recommend Sanofi's Jevtana (cabazitaxel), in combination with prednisone or prednisolone, as a second-line treatment for prostate cancer. ...
NICE rejects Sanofi's JevtanaInPharm
Negative NICE guidance for Sanofi prostate cancer drugThe Pharma Letter
Sanofi's Jevtana Cancer Drug Rejected by UK Cost AgencyBusinessWeek

all 9 news articles »